Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

Dimopoulos, Meletios A.; Moreau, Philippe; Palumbo, Antonio; Joshua, Douglas; Pour, Ludek; Hajek, Roman; Facon, Thierry; Ludwig, Heinz; Oriol, Albert; Goldschmidt, Hartmut; Rosinol, Laura; Straub, Jan; Suvorov, Aleksandr; Araujo, Carla; Rimashevskaya, Elena; Pika, Tomas; Gaidano, Gianluca; Weisel, Katja; Goranova-Marinova, Vesselina; Schwarer, Anthony; Minuk, Leonard; Masszi, Tamas; Karamanesht, Ievgenii; Offidani, Massimo; Hungria, Vania; Spencer, Andrew; Orlowski, Robert Z.; Gillenwater, Heidi H.; Mohamed, Nehal; Feng, Shibao; Chng, Wee-Joo

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

Autor(en):

Dimopoulos, Meletios A.; Moreau, Philippe; Palumbo, Antonio; Joshua, Douglas; Pour, Ludek; Hajek, Roman; Facon, Thierry; Ludwig, Heinz; Oriol, Albert; Goldschmidt, Hartmut; Rosinol, Laura; Straub, Jan; Suvorov, Aleksandr; Araujo, Carla; Rimashevskaya, Elena; Pika, Tomas; Gaidano, Gianluca; Weisel, Katja; Goranova-Marinova, Vesselina; Schwarer, Anthony; Minuk, Leonard; Masszi, Tamas; Karamanesht, Ievgenii; Offidani, Massimo; Hungria, Vania; Spencer, Andrew; Orlowski, Robert Z.; Gillenwater, Heidi H.; Mohamed, Nehal; Feng, Shibao; Chng, Wee-Joo

Tübinger Autor(en):

Weisel, Katja

Erschienen in:

Lancet Oncology (2016), Bd. 17, H. 1, S. 27-38

Verlagsangabe:

Elsevier Science Inc

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1016/S1470-2045(15)00464-7

ISSN:

1474-5488